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Case Report
A case of isolated metastatic hepatocellular carcinoma 
arising from the pelvic bone
Kyu Sik Jung1, Kyeong Hye Park1, Young Eun Chon1, Sa Ra Lee2, Young Nyun Park2, 
Do Yun Lee3, Jin Sil Seong4, and Jun Yong Park1
Departments of 1Internal Medicine, 2Pathology, 3Radiology, and 4Radiation Oncology, 
Yonsei University College of Medicine, Seoul, Korea
Reports of metastatic hepatocellular carcinoma (HCC) without a primary liver tumor are rare. Here we present a case of 
isolated HCC that had metastasized to the pelvic bone without a primary focus. A 73-year-old man presented with severe 
back and right-leg pain. Radiological examinations, including computed tomography (CT) and magnetic resonance 
imaging (MRI), revealed a huge mass on the pelvic bone (13×10 cm). He underwent an incisional biopsy, and the results 
of the subsequent histological examination were consistent with metastatic hepatocellular carcinoma. The tumor cells 
were positive for cytokeratin (AE1/AE3), hepatocyte paraffin 1, and glypican-3, and negative for CD56, chromogranin A, 
and synaptophysin on immunohistochemical staining. Examination of the liver by CT, MRI, positron-emission tomography 
scan, and angiography produced no evidence of a primary tumor. Radiotherapy and transarterial chemoembolization 
were performed on the pelvic bone, followed by systemic chemotherapy. These combination treatments resulted in tumor 
regression with necrotic changes. However, multiple lung metastases developed 1 year after the treatment, and the 
patient was treated with additional systemic chemotherapy. (Korean J Hepatol 2012;18:89-93)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most 
common cancers and its incidence is increasing worldwide.1 
As the treatment of HCC has remarkably improved, the 
survival of patients with HCC has been prolonged. 
Consequently, extrahepatic metastasis of HCC is now 
diagnosed more frequently and the incidence of bone 
metastasis from HCC is also increasing.2,3 However, cases of 
extrahepatic HCC without a detectable primary liver tumor 
have rarely been reported; in fact, bone metastasis from 
HCC, single or multiple, without the presence of a primary 
tumor has been reported in only six cases worldwide.4-9 
Because of insufficient experience with these cases, 
diagnostic and treatment approaches for these patients are 
challenging. Here, we present a case of metastatic HCC 
arising from the pelvic bone without a primary focus.
CASE REPORT
A 73-year-old man was admitted to our hospital for 
evaluation of severe back pain and right leg pain for 1 
month. The medical history of patient revealed that he was 
diagnosed as a hepatitis B virus (HBV) carrier about 20 
years earlier, but was lost to follow up. The patient was not a 
heavy drinker or smoker. There was no significant family 
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Figure 1. Pelvic magnetic resonance imaging (MRI). A 13×10-cm bone mass was found in the right iliac bone. (A, C, D: T1-weighted 
images, B: T2-weighted image).
history. On physical examination, a palpable and hard mass 
was noted in the right pelvic area. Hepatomegaly, liver 
masses, and ascites were absent. Initial laboratory findings 
were as follows: white blood cell count 4,830/μL, hemoglobin 
15.2 g/dL, platelets 138,000/μL, total protein 7.8 g/dL, 
albumin 4.4 g/dL, aspartate aminotransferase (AST) 31 
IU/L, alanine aminotransferase (ALT) 35 IU/L, total 
bilirubin 1.0 mg/dL, alkaline phosphate 98 IU/L, proth-
rombin time 14 second (INR 1.21), alpha-fetoprotein (AFP) 
15.01 ng/mL, and protein induced by vitamin K absence or 
antagonist-II (PIVKA-II) 864 mAU/mL. Hepatitis B virus 
surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) 
were positive. Hepatitis B e antibody (HBeAb), HBV-DNA 
with polymerase chain reaction, and serological markers of 
hepatitis C were negative. He belonged to Child-Turcotte- 
Pugh class A.
For evaluation of the pelvic mass, computed tomography 
(CT) and magnetic resonance imaging (MRI) scans were 
performed. They demonstrated a 13×10 cm expansile mass 
that involved the right iliac bone (Fig. 1). The patient 
underwent an incisional biopsy with the impression of a 
malignant bone tumor. However, on pathological examination, 
the tumor was composed of polygonal cells with ample 
cytoplasm and trabecular pattern. In immunohistochemical 
stains, these tumor cells were positive for cytokeratin 
(AE1/AE3), hepatocyte paraffin 1 (HepPar1), and glypican-3, 
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Figure 2. Microscopic findings of the pelvic bone mass. The tumor was a hepatocellular carcinoma with a trabecular pattern (A: 
hematoxylin and eosin, ×200). The tumor cells were immunopositive for cytokeratin (AE1/AE3) (B: ×200), hepatocyte paraffin 1 (C: 
×200), and glypican-3 (D: ×200).
which confirmed the diagnosis of HCC (Fig. 2). Tumor cells 
were negative for CD56, chromogranin A and synapto-
physin, which are the markers of neuroendocrine 
differentiation. To find the primary focus, abdominal CT, 
MRI, positron emission tomography (PET) scans and 
angiography were performed. However, no tumor was found 
in the liver in these radiologic examinations. 
We diagnosed this case as an isolated metastatic HCC of 
the pelvic bone without the presence of a primary cancer in 
the liver. Surgical resection of the tumor was recommended, 
but the patient refused an operation because of old age and 
the large size of the tumor. Instead, we decided to treat him 
with combined modalities. He started radiotherapy in the 
pelvic area with a total dose of 5,100 cGy in 17 fractions. 
One week after the end of radiotherapy, transarterial 
chemoembolization (TACE) was performed in the metastatic 
HCC of the pelvic bone via the right internal iliac artery 
(adriamycin 50 mg and 20 mL of lipiodol). Then, the patient 
was treated with five cycles of systemic chemotherapy 
based on 5-Fluorouracil (5-FU, 1,000 mg/m2 on days 1, 2, 
and 3) and cisplatin (90 mg/m2 on day 2 every 4 weeks). 
After the completion of chemotherapy, the tumor became 
almost necrotic. The AFP and PIVKA-II levels decreased 
to the normal ranges (2.85 ng/mL and 28 mAU/mL, 
respectively). As the treatment resulted in near complete 
regression of the tumor, the patient underwent close follow- 
up without chemotherapy. However, 12 months after 
chemotherapy, a CT scan revealed multiple lung metastases 
in both lungs with increasing AFP and PIVKA-II levels (182 
ng/mL and 38 mAU/mL, respectively). He was treated with 
two cycles of systemic chemotherapy with the same 
regimen (5-FU 1000 mg/m2 on days 1, 2 and 3 and cisplatin 
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90 mg/m2 on day 2). After two cycles of chemotherapy, the 
patient refused additional chemotherapy and we provided 
him with supportive care thereafter. Even though the lung 
metastases were newly developed, primary HCC had not 
been detected in the sequential radiological examinations, 
including abdominal CT and PET CT scans.
DISCUSSION
In this case, the final diagnosis was an isolated pelvic 
bone metastasis from HCC with unknown primary origin. 
Extrahepatic metastases from unknown primary HCC are 
exceptionally rare and only a few case reports of bone 
metastasis have been documented.4-9 The hypothesis for 
explaining this unusual phenomenon is that the metastases 
are from a microhepatocellular carcinoma, which regressed 
spontaneously or was destroyed by the activated immune 
system.6,7,10 However, the carcinogenesis mechanism as well 
as the natural history of this rare phenomenon is not 
well-known yet.7 Thus, the diagnostic approach and 
treatment have been performed on an individual basis.
Although the nature of tumor cell could be confirmed by 
histological examination including immunohistochemical 
stains, we had to make a differential diagnosis with hepatoid 
adenocarcinoma and HCC development from ectopic 
liver.11-13 Indeed, as there is no specific pathologic finding 
that could distinguish metastatic HCC from hepatoid 
adenocarcinoma or HCC arising from ectopic liver, 
information about involved organ, the presence of chronic 
liver disease and the degree of liver disease have been used 
as additional basis for differential diagnosis in previous 
studies.4-9 For example, reporting on a case of HCC in chest 
wall without unknown origin, Asselah et al4 made a final 
diagnosis of HCC arising in ectopic liver tissue, considering 
that the patient was not at high risk factors of HCC 
development and that the tumor developed in only parietal 
muscular tissue, which is an uncommon site for an HCC 
metastasis. In our case, we also had to make a diagnosis 
considering not only the pathological examination but also 
the clinical features of our case, even though we made a 
different diagnosis comparing from previous case. At first, 
in our case, neither hepatoid cells with large eosinophilic 
cytoplasm nor normal liver tissue was observed at 
microscopic histological examination, which could be 
shown in hepatoid adenocarcinoma or HCC arising from 
ectopic liver.9,14 Second, 1 year after treatment, new 
metastases developed in lung, which is the most common 
metastatic site of HCC.3,15 In previous studies, lung 
metastases from hepatoid adenocarcinoma or HCC arising 
from ectopic liver have rarely been reported.16,17 Moreover, 
to our knowledge, there is no report that hepatoid adeno-
carcinoma or ectopic liver developed from pelvic bone, even 
though they can originate from various organs.14,16,18 For 
these reasons, we made a final diagnosis of metastatic 
HCC with unknown primary HCC. However, we admit 
that our diagnosis may not be definitely confirmed in that 
histological was insufficient, as the specimen obtained from 
an incisional biopsy did not have non-cancerous tissue. 
It can also be argued that a liver biopsy would be 
necessary for evaluating primary HCC in the liver. Coban et 
al19 reported a patient who presented an isolated extrahepatic 
HCC of the chest wall without a primary focus. The patient 
had HBV-related liver cirrhosis, and a diffusely nodular and 
heterogeneous echogenic pattern was shown in ultrasono-
graphy, but there was no evidence of HCC in the liver. 
However, a liver biopsy was performed, and histological 
examination confirmed a diffuse type of HCC. But, we 
thought that the benefit of a biopsy was uncertain in our case 
because the patient had no clinical evidence of liver 
cirrhosis, and the liver parenchyma was smooth without a 
mass or infiltrating lesion. Moreover, we performed CT, 
MRI, PET scans, and angiography to find primary HCC, but 
no evidence of a primary liver tumor was found. Finally, we 
thought that liver biopsy was unnecessary in our patient. 
However, even though a primary tumor was not found in our 
case, an intensive search for primary HCC should be carried 
out when extrahepatic metastasis is observed as the initial 
presentation.
 Although there is no standard treatment for extrahepatic 
metastasis without a primary focus, aggressive treatment 
including surgical resection results in good prognosis if a 
solitary lesion exists.4,6,8,9 Iosca et al6 reported a case that 
presented with an isolated left iliac bone metastasis from a 
primary unknown HCC. The patient was treated with TACE 
followed by the surgical resection. He was alive without 
recurrence over 45 months. However, we could not perform 
surgical resection because our patient refused operation. 
Instead, we treated him with combined modalities including 
radiotherapy, TACE and systemic chemotherapy. Although 
chemotherapy and radiotherapy have not been demonstrated 
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to increase the survival rate of HCC patients with bone 
metastasis, their ability to reduce pain and to increase 
quality of life has been reported in previous studies.15,20 In 
our case, back and leg pain were relieved after treatment. 
Moreover, TACE was performed without complications to 
the pelvic bone metastasis in our case. Indeed, TACE was 
successfully performed for bone metastasis of HCC in 
previous studies,6,21 and these results suggest that TACE 
could be considered as a treatment option for a bone 
metastasis from HCC. Even though multiple lung metastases 
developed, the tumor was well controlled for 12 months 
after the treatment. In conclusion, we think that individualized 
and multimodality treatment would be beneficial in such 
cases.
In summary, we reported a rare case of metastatic HCC of 
the pelvic bone without a known primary origin. In such 
cases, tissue biopsy and radiological examination should be 
performed and diagnosis should be made based on both 
pathological examination and clinical features. Individualized 
and combined modality treatment could be considered in 
such cases.
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